Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hope for IPF cough: experimental drug shows promise in early trial

NCT ID NCT05185089

Symptom relief Sponsor: Nerre Therapeutics Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a drug called orvepitant to see if it can reduce chronic coughing in people with idiopathic pulmonary fibrosis (IPF), a serious lung disease. About 80 adults with IPF and persistent cough took either orvepitant or a placebo in two separate periods, and researchers measured changes in cough severity using a daily scale. The goal was to find a safe and effective way to ease this troubling symptom.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

80 people

The number who actually took part.

Started

Aug 2022

Finished

Jun 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Diagnosis of IPF established according to the 2018 or 2022 joint ATS/ERS/JRS/ALAT Clinical Practice Guideline * FEV1/FVC ratio ≥0.65 at the screening visit * Haemoglobin-corrected diffusion capacity of carbon monoxide (Hb-corrected DLCO) ≥25% within 12 months of the screening visit * Arterial oxygen saturation on room air or oxygen ≥90% at Screening * Life expectancy of at least 12 months * Cough that is attributed to IPF, which has not responded to anti-tussive treatment, and which has been present for at least 8 weeks prior to Screening * Mean daily IPF Coughing Severity Scale score ≥5 (after rounding) during the second week of the baseline assessment period Key Exclusion Criteria: * Recent respiratory tract infection (\<8 weeks prior to Screening) * Recent acute exacerbation of IPF (\<8 weeks prior to Screening) * Current smokers or ex-smokers with \<6 months' abstinence prior to Screening * Emphysema ≥50% on high-resolution computed tomography, or the extent of emphysema is greater than the extent of fibrosis according to the reported results of the most recent scan * Mean early morning cough scale score ≥5 and rest of the day cough scale score \<5 (after rounding) during the second week of the baseline assessment period (assessed at Visit 2) * Cough that is predominantly productive in nature and attributable to lung pathology such as chronic bronchitis or bronchiectasis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cough are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Cough idiopathic pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cough Idiopathic pulmonary fibrosis

Contacts and locations

Locations

  • Altnagelvin Area Hospital

    Londonderry, Northern Ireland, BT47 6SB, United Kingdom

  • American Health Research

    Charlotte, North Carolina, 28277, United States

  • Antrim Area Hospital

    Antrim, Northern Ireland, BT41 2RL, United Kingdom

  • Baylor University

    Dallas, Texas, 75246, United States

  • Castle Hill Hospital

    Cottingham, Hull, HU16 5JQ, United Kingdom

  • Churchill Hospital

    Headington, Oxford, OX3 7LE, United Kingdom

  • Clear Lake Health

    Webster, Texas, 77598, United States

  • Erasmus University Medical Centre

    Rotterdam, 3015 GD, Netherlands

  • Guy's Hospital

    London, SE1 9RT, United Kingdom

  • Heartlands Hospital

    Birmingham, B9 5SS, United Kingdom

  • Isala Ziekenhuis

    Zwolle, 8025 AB, Netherlands

  • Jadestone Clinical Research, LLC

    Silver Spring, Maryland, 20904, United States

  • Loyola University Chicago

    Maywood, Illinois, 60153, United States

  • MAC Clinical Research

    Prescot, Merseyside, L34 1BH, United Kingdom

  • MAC Clinical Research

    Barnsley, South Yorkshire, S75 3DL, United Kingdom

  • MAC Clinical Research

    Leeds, West Yorkshire, LS10 1DU, United Kingdom

  • MAC Clinical Research

    Manchester, M13 9NQ, United Kingdom

  • Mayo Clinic

    Rochester, Minnesota, 55905, United States

  • Medical University of South Carolina

    Charleston, South Carolina, 29424, United States

  • National Jewish Health

    Denver, Colorado, 80206, United States

  • Nottingham City Hospital

    Nottingham, NG5 1PB, United Kingdom

  • Perth Royal Infirmary

    Perth, Perth and Kinross, PH1 1NX, United Kingdom

  • PulmonIx, LLC

    Greensboro, North Carolina, 27403, United States

  • Royal Berkshire Hospital

    Reading, Berkshire, RG1 5AN, United Kingdom

  • Royal Devon and Exeter Hospital

    Exeter, EX2 5DW, United Kingdom

  • Royal Infirmary of Edinburgh

    Edinburgh, Scotland, EH16 4SA, United Kingdom

  • Royal Papworth Hospital

    Cambridge, CB2 0AY, United Kingdom

  • Sint Antonius Hospital

    Nieuwegein, 3435 CM, Netherlands

  • Southampton General Hospital

    Southampton, SO16 6YD, United Kingdom

  • Temple University

    Philadelphia, Pennsylvania, 19140, United States

  • University of California

    San Francisco, California, 94143, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Southern California

    Los Angeles, California, 90033, United States

  • University of Utah

    Salt Lake City, Utah, 84108, United States

  • University of Virginia Health System

    Charlottesville, Virginia, 22908, United States

  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37204, United States

  • Zuyderland Medical Centre

    Heerlen, 6419 PC, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.